{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"1.76"},{"groupId":"OG001","spread":"0","value":"5.88"},{"groupId":"OG002","spread":"0.80","value":"3.03"},{"groupId":"OG003","spread":"5.30","value":"4.91"},{"groupId":"OG004","spread":"1.18","value":"2.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Week 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.61","value":"1.29"},{"groupId":"OG001","spread":"4.17","value":"5.86"},{"groupId":"OG002","spread":"1.99","value":"4.67"},{"groupId":"OG003","spread":"2.34","value":"4.40"},{"groupId":"OG004","spread":"1.01","value":"1.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.60","value":"3.96"},{"groupId":"OG001","spread":"1.36","value":"4.27"},{"groupId":"OG002","spread":"1.30","value":"3.72"},{"groupId":"OG003","spread":"0.84","value":"2.74"},{"groupId":"OG004","spread":"0","value":"1.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"3.82"},{"groupId":"OG001","spread":"1.91","value":"3.66"},{"groupId":"OG002","spread":"1.42","value":"3.73"},{"groupId":"OG003","spread":"0.99","value":"3.23"},{"groupId":"OG004","spread":"301.13","value":"217.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"3.30"},{"groupId":"OG001","spread":"1.46","value":"3.94"},{"groupId":"OG002","spread":"2.06","value":"3.39"},{"groupId":"OG003","spread":"0.87","value":"2.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"3.86"},{"groupId":"OG001","spread":"11.42","value":"10.71"},{"groupId":"OG002","spread":"0.70","value":"2.87"},{"groupId":"OG003","spread":"1.56","value":"3.03"},{"groupId":"OG004","spread":"0","value":"0.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"Week 9"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"The cytokine was quantitated using V-PLEX Human Proinflammatory Panel, a multiplex immunoassay kit developed by Meso Scale Diagnostics (MSD). A four-parameter logistic fit calibration curve was generated and used to calculate concentrations in tested samples. Analyses were performed at pre-treatment and 1 week following the first dose of drug and additionally at 2, 3, 6, and 9 weeks following the course 1 drug dose if feasible. The mean concentration of IL-8 in pg/ml was reported with a standard deviation. When only 1 participant analyzed, the standard deviation was reported as 0 (rather than undefined).","dispersionType":"Standard Deviation","groups":[{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.1 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG000","title":"Stratum 1, Dose Level 1"},{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Stratum 1, Dose Level 2"},{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG002","title":"Stratum 1, Dose Level 3"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG003","title":"Stratum 2, Dose Level 2"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG004","title":"Stratum 2, Dose Level 3"}],"paramType":"MEAN","populationDescription":"Not all patients had data available at every time point.","reportingStatus":"POSTED","timeFrame":"Pre-treatment (week 0), 1 week, 2 week, 3 weeks, 6 weeks and 9 weeks post-treatment","title":"Concentration of the Cytokine Interleukin-8 (IL-8)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"pg/ml"}